The most common nPTs of PD‐1 inhibitors were peripheral neuropathy(N = 978, 10.7%), dizziness (N = 942, 10.3%), and myasthenia gravis (N = 675, 7.4%) (Figure 3a). This evidence concerns the gene PDCD1 and myasthenia gravis.